Stay updated on Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.4.2; removed the prior Revision: v3.4.1 and the government funding status notice.SummaryDifference0.4%

- Check8 days agoChange DetectedA system-wide notice about a lapse in government funding was added and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check15 days agoChange DetectedAdds a glossary toggle and a new QC label 'Last Update Submitted that Met QC Criteria', and updates FEAR Act text plus version to v3.4.0 while removing the older QC label and older FEAR Act wording. These are UI/metadata updates and do not change the core study content.SummaryDifference0.2%

- Check22 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedAdded a Locations section listing Texas as a study site and removed the separate Texas Locations footer entry; the HHS Vulnerability Disclosure link and the prior revision note were also removed.SummaryDifference0.2%

- Check73 days agoChange DetectedFooter revision label updated from v3.3.1 to v3.3.2; no changes to study content or data are observed.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with REOLYSIN in Pancreatic Cancer Clinical Trial page.